Literature DB >> 19247366

AAV9: a potential blood-brain barrier buster.

Fredric P Manfredsson1, Aaron C Rising, Ronald J Mandel.   

Abstract

Mesh:

Year:  2009        PMID: 19247366      PMCID: PMC2835088          DOI: 10.1038/mt.2009.15

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  29 in total

1.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

2.  Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.

Authors:  R W Walters; S M Yi; S Keshavjee; K E Brown; M J Welsh; J A Chiorini; J Zabner
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

3.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

4.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.

Authors:  Corinna Burger; Oleg S Gorbatyuk; Margaret J Velardo; Carmen S Peden; Philip Williams; Sergei Zolotukhin; Paul J Reier; Ronald J Mandel; Nicholas Muzyczka
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

5.  Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2.

Authors:  K Qing; C Mah; J Hansen; S Zhou; V Dwarki; A Srivastava
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

6.  AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection.

Authors:  C Summerford; J S Bartlett; R J Samulski
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

7.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Authors:  Kevin D Foust; Emily Nurre; Chrystal L Montgomery; Anna Hernandez; Curtis M Chan; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

8.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells.

Authors:  P L Hermonat; N Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

9.  Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice.

Authors:  Marco A Passini; Deborah J Watson; Charles H Vite; Daniel J Landsburg; Alyson L Feigenbaum; John H Wolfe
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

Authors:  Brian K Kaspar; Jerònia Lladó; Nushin Sherkat; Jeffrey D Rothstein; Fred H Gage
Journal:  Science       Date:  2003-08-08       Impact factor: 47.728

View more
  32 in total

1.  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.

Authors:  Lluis Samaranch; Ernesto A Salegio; Waldy San Sebastian; Adrian P Kells; Kevin D Foust; John R Bringas; Clementine Lamarre; John Forsayeth; Brian K Kaspar; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-03-28       Impact factor: 5.695

2.  AAV9: over the fence and into the woods . . .

Authors:  John R Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2011-06       Impact factor: 11.454

3.  Positron emission tomography reporter gene strategy for use in the central nervous system.

Authors:  Tom Haywood; Corinne Beinat; Gayatri Gowrishankar; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-23       Impact factor: 11.205

4.  Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound.

Authors:  Emmanuel Thévenot; Jessica F Jordão; Meaghan A O'Reilly; Kelly Markham; Ying-Qi Weng; Kevin D Foust; Brian K Kaspar; Kullervo Hynynen; Isabelle Aubert
Journal:  Hum Gene Ther       Date:  2012-10-15       Impact factor: 5.695

5.  Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.

Authors:  Mai K Elmallah; Darin J Falk; Sushrusha Nayak; Roland A Federico; Milapjit S Sandhu; Amy Poirier; Barry J Byrne; David D Fuller
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

Review 6.  Gene therapy for Mucopolysaccharidoses.

Authors:  Kazuki Sawamoto; Hui-Hsuan Chen; Carlos J Alméciga-Díaz; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-12-26       Impact factor: 4.797

7.  Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1.

Authors:  Randy J Chandler; Ian M Williams; Alana L Gibson; Cristin D Davidson; Arturo A Incao; Brandon T Hubbard; Forbes D Porter; William J Pavan; Charles P Venditti
Journal:  Hum Mol Genet       Date:  2017-01-01       Impact factor: 6.150

8.  Intravenous delivery of adeno-associated viral vector serotype 9 mediates effective gene expression in ischemic stroke lesion and brain angiogenic foci.

Authors:  Fanxia Shen; Robert Kuo; Marine Milon-Camus; Zhenying Han; Lidan Jiang; William L Young; Hua Su
Journal:  Stroke       Date:  2012-12-18       Impact factor: 7.914

9.  Over the barrier and through the blood: to CNS delivery we go.

Authors:  Kevin D Foust; Brian K Kaspar
Journal:  Cell Cycle       Date:  2009-12-05       Impact factor: 4.534

10.  Histochemical localization of palmitoyl protein thioesterase-1 activity.

Authors:  Joshua T Dearborn; Subramania Ramachandran; Charles Shyng; Jui-Yun Lu; Jonah Thornton; Sandra L Hofmann; Mark S Sands
Journal:  Mol Genet Metab       Date:  2015-11-11       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.